Evaluation of efficacy and safety of endovascular injection sclerotherapy in females with Primary pelvic congestion syndrome

Abstract

Background: Pelvic congestion syndrome (PCS) is one of the pelvic venous syndromes that is frequently misdiagnosed.

Aim and objectives: This study aimed to evaluate the effectiveness, Safety and early clinical outcome and patients' satisfaction after pelvic congestion syndrome (PCS) injection sclerotherapy in female patients who suffered from chronic pelvic pain that initially consulted for lower limb venous insufficiency.

Patients and methods: This was a retrospective clinical study carried on 40 consecutive female patients with pelvic congestion syndrome at Gynecological clinic, Vascular and endovascular Surgery Unit - Minia University Hospitals, Egypt from April 2021 to February 2023.

Results: Number of patients with incompetent Saphenous-femoral and incompetent Saphenous-popliteal junction in the study population, dilated Greater saphenous vein and Short saphenous vein was 14 (35%), 1 (2.5%), 16 (40%) and 2 (5%) respectively. Pain with menses Baseline and 1 month 3 months, 6 months and 12 months later ranged from (4 to 7, 2 to 4, 2 to 3, 1 to 3 and1 to 3) respectively with mean ± SD = 5.3 ± 0.91, 2.62 ± 0.59, 2.38 ± 0.49, 1.98 ± 0.42 and 1.8 ± 0.46) respectively. Number of patients with improved condition in the study population was 25 (62.50%).  Number of patients with no Complications in the study population was 33 (82.50%).

Conclusion: Injection sclerotherapy of pelvic veins has been shown to be an effective and safe technique, resulting in relevant clinical success, with an overall improvement of pain and other symptoms.